应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
EWTX Edgewise Therapeutics, Inc.
交易中 05-19 15:49:24 EDT
31.46
-0.26
-0.82%
最高
32.09
最低
31.02
成交量
86.67万
今开
31.52
昨收
31.72
日振幅
3.37%
总市值
33.75亿
流通市值
19.14亿
总股本
1.07亿
成交额
2,743万
换手率
1.42%
流通股本
6,085万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Edgewise Therapeutics公布2026年第一季度财报 肌肉萎缩症与心血管适应症临床项目取得进展
美股速递 · 05-07
Edgewise Therapeutics公布2026年第一季度财报 肌肉萎缩症与心血管适应症临床项目取得进展
Edgewise Therapeutics计划于2026年下半年启动EDG-7500针对梗阻性和非梗阻性HCM患者的III期临床试验
美股速递 · 01-13
Edgewise Therapeutics计划于2026年下半年启动EDG-7500针对梗阻性和非梗阻性HCM患者的III期临床试验
Edgewise Therapeutics公司预计2026年上半年公布Edg-7500治疗肥厚型心肌病的二期试验结果
美股速递 · 01-13
Edgewise Therapeutics公司预计2026年上半年公布Edg-7500治疗肥厚型心肌病的二期试验结果
Edgewise Therapeutics, Inc.：预计2026年第二季度公布完整12周Part D数据，计划在2026年第四季度启动三期试验
美股速递 · 2025-12-24
Edgewise Therapeutics, Inc.：预计2026年第二季度公布完整12周Part D数据，计划在2026年第四季度启动三期试验
Edgewise Therapeutics, Inc.盘中异动 早盘大幅下挫5.05%
市场透视 · 2025-12-03
Edgewise Therapeutics, Inc.盘中异动 早盘大幅下挫5.05%
Edgewise Therapeutics任命商业生物科技高管Christopher Martin为董事会成员
美股速递 · 2025-11-20
Edgewise Therapeutics任命商业生物科技高管Christopher Martin为董事会成员
Edgewise Therapeutics第三季度运营费用为4685.8万美元
投资观察 · 2025-11-20
Edgewise Therapeutics第三季度运营费用为4685.8万美元
Edgewise Therapeutics, Inc.2024财年实现净利润-1.34亿美元，同比减少34.00%
市场透视 · 2025-03-09
Edgewise Therapeutics, Inc.2024财年实现净利润-1.34亿美元，同比减少34.00%
Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。
金融界 · 2025-03-08
Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。
Edgewise Therapeutics, Inc.盘中异动 快速上涨5.02%报28.05美元
市场透视 · 2025-03-07
Edgewise Therapeutics, Inc.盘中异动 快速上涨5.02%报28.05美元
Edgewise Therapeutics, Inc.盘中异动 快速跳水5.10%
市场透视 · 2025-02-25
Edgewise Therapeutics, Inc.盘中异动 快速跳水5.10%
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.02%
市场透视 · 2025-02-22
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.02%
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.00%报26.66美元
市场透视 · 2025-02-19
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.00%报26.66美元
Edgewise Therapeutics, Inc.盘中异动 大幅上涨5.83%
市场透视 · 2025-01-15
Edgewise Therapeutics, Inc.盘中异动 大幅上涨5.83%
【纳斯达克生物科技指数收跌1.84%】 成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。
金融界 · 2025-01-15
【纳斯达克生物科技指数收跌1.84%】 成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。
Edgewise Therapeutics, Inc.盘中异动 早盘急速下挫5.70%报26.14美元
市场透视 · 2025-01-06
Edgewise Therapeutics, Inc.盘中异动 早盘急速下挫5.70%报26.14美元
Edgewise Therapeutics, Inc.盘中异动 早盘股价大涨5.80%报33.94美元
市场透视 · 2024-11-27
Edgewise Therapeutics, Inc.盘中异动 早盘股价大涨5.80%报33.94美元
Edgewise Therapeutics, Inc.2024财年第三财季实现净利润-34.13百万美元，同比减少32.75%
市场透视 · 2024-11-16
Edgewise Therapeutics, Inc.2024财年第三财季实现净利润-34.13百万美元，同比减少32.75%
Edgewise Therapeutics, Inc.盘中异动 下午盘大幅下跌5.06%
市场透视 · 2024-11-14
Edgewise Therapeutics, Inc.盘中异动 下午盘大幅下跌5.06%
Edgewise Therapeutics, Inc.盘中异动 下午盘大幅下挫5.02%
市场透视 · 2024-11-08
Edgewise Therapeutics, Inc.盘中异动 下午盘大幅下挫5.02%
加载更多
公司概况
公司名称：
Edgewise Therapeutics, Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Edgewise Therapeutics, Inc.于2017年5月在特拉华州注册成立。该公司是一家以科学为驱动的生物技术公司，专注于开发针对严重肌肉疾病的疗法，最初目标是罕见神经肌肉和心脏疾病。其主要候选药物sevasemten是一种口服小分子抑制剂，正处于治疗杜氏肌营养不良和贝克尔肌营养不良的后期临床开发阶段。
发行价格：
--
{"stockData":{"symbol":"EWTX","market":"US","secType":"STK","nameCN":"Edgewise Therapeutics, Inc.","latestPrice":31.46,"timestamp":1779220163649,"preClose":31.72,"halted":0,"volume":866688,"delay":0,"changeRate":-0.008196721311475348,"floatShares":60849799,"shares":107270521,"eps":-1.663051,"marketStatus":"交易中","change":-0.26,"latestTime":"05-19 15:49:24 EDT","open":31.52,"high":32.09,"low":31.02,"amount":27427191.114240002,"amplitude":0.033733,"askPrice":31.46,"askSize":100,"bidPrice":31.44,"bidSize":184,"shortable":3,"etf":0,"ttmEps":-1.663051,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1779220800000},"marketStatusCode":2,"adr":0,"listingDate":1616731200000,"exchange":"NASDAQ","adjPreClose":31.72,"preHourTrading":{"tag":"盘前","latestPrice":31.45,"preClose":31.72,"latestTime":"09:26 EDT","volume":439,"amount":13912.932869999999,"timestamp":1779197179469,"change":-0.27,"changeRate":-0.008512,"amplitude":0.103405},"postHourTrading":{"tag":"盘后","latestPrice":31.72,"preClose":31.72,"latestTime":"17:44 EDT","volume":21766,"amount":690431.24,"timestamp":1779140643405,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.875314,"impliedVol":0.8811,"impliedVolPercentile":0.7052},"requestUrl":"/m/hq/s/EWTX","defaultTab":"news","newsList":[{"id":"1132448595","title":"Edgewise Therapeutics公布2026年第一季度财报 肌肉萎缩症与心血管适应症临床项目取得进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1132448595","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132448595?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:01","pubTimestamp":1778155311,"startTime":"0","endTime":"0","summary":"生物制药公司Edgewise Therapeutics披露了2026年首季度财务业绩，同时宣布其在肌肉萎缩症和心血管疾病领域的临床开发计划获得实质性推进。财报显示，公司当期研发投入同比增长显著，主要资金用于加速核心候选药物的临床研究。目前，针对杜氏肌营养不良症的实验性疗法已进入关键试验阶段，而用于治疗特定心血管适应症的新药也完成了患者招募里程碑。公司管理层表示，现金流状况足以支持未来两年的运营计划，并将持续通过临床数据验证其创新疗法的科学价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169638993","title":"Edgewise Therapeutics计划于2026年下半年启动EDG-7500针对梗阻性和非梗阻性HCM患者的III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1169638993","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169638993?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:09","pubTimestamp":1768309759,"startTime":"0","endTime":"0","summary":"生物制药公司Edgewise Therapeutics近日宣布，其核心候选药物EDG-7500将于2026年下半年正式进入III期临床试验阶段。该试验将同时针对梗阻性及非梗阻性肥厚型心肌病患者群体展开，标志着公司在该疾病领域研发进程的重要突破。EDG-7500作为新一代心肌肌球蛋白抑制剂，此前已通过II期临床试验验证其安全性与初步疗效。这一研发进展不仅为HCM患者提供了新的治疗希望，更凸显了Edgewise Therapeutics在心血管疾病创新疗法领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118951729","title":"Edgewise Therapeutics公司预计2026年上半年公布Edg-7500治疗肥厚型心肌病的二期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1118951729","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118951729?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:06","pubTimestamp":1768309589,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics公司宣布，其针对肥厚型心肌病（HCM）研发的创新药物Edg-7500，预计将在2026年上半年获得二期临床试验的关键数据。这一进展标志着公司在心血管疾病治疗领域的重要里程碑，有望为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128361463","title":"Edgewise Therapeutics, Inc.：预计2026年第二季度公布完整12周Part D数据，计划在2026年第四季度启动三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1128361463","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128361463?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:01","pubTimestamp":1766581271,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics, Inc.：预计2026年第二季度公布完整12周Part D数据，计划在2026年第四季度启动三期试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588848057","title":"Edgewise Therapeutics, Inc.盘中异动 早盘大幅下挫5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588848057","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588848057?lang=zh_cn&edition=full","pubTime":"2025-12-03 00:17","pubTimestamp":1764692235,"startTime":"0","endTime":"0","summary":"北京时间2025年12月03日00时17分，Edgewise Therapeutics, Inc.股票出现波动，股价大幅下跌5.05%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，Polyrizon Ltd.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Ethzilla Corporation涨幅较大，Polyrizon Ltd.、Clearmind Medicine Inc.、Jasper Therapeutics, Inc.较为活跃，换手率分别为8412.37%、323.17%、185.84%，振幅较大的相关个股有Polyrizon Ltd.、Akari Therapeutics Plc、Sonnet Biotherapeutics Holdings, Inc.，振幅分别为79.43%、70.43%、50.65%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。该公司的候选产品是Sevasemten和EDG-7500。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120300171595270e55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120300171595270e55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","BK4539","EWTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153959997","title":"Edgewise Therapeutics任命商业生物科技高管Christopher Martin为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1153959997","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153959997?lang=zh_cn&edition=full","pubTime":"2025-11-20 21:01","pubTimestamp":1763643706,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics任命商业生物科技高管Christopher Martin为董事会成员","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143839149","title":"Edgewise Therapeutics第三季度运营费用为4685.8万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143839149","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143839149?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:57","pubTimestamp":1763571451,"startTime":"0","endTime":"0","summary":"11月6日讯 - Edgewise Therapeutics第三季度运营收入为-4685.8万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518440030","title":"Edgewise Therapeutics, Inc.2024财年实现净利润-1.34亿美元，同比减少34.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440030","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518440030?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449679,"startTime":"0","endTime":"0","summary":"3月9日，Edgewise Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.34亿美元，同比减少34.00%；其中营业收入为0.00美元，每股基本收益为-1.45美元。从资产负债表来看，Edgewise Therapeutics, Inc.总负债27.60百万美元，其中短期债务996000.00美元，资产负债比为0.18，流动比率为0.20。机构评级：截至2025年3月9日，当前有9家机构对Edgewise Therapeutics, Inc.目标价做出预测，其中目标均价为47.44美元，其中最低目标价为30.00美元，最高目标价为56.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000248abef98a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000248abef98a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517146142","title":"Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517146142","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517146142?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:25","pubTimestamp":1741386325,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08062548605321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517193704","title":"Edgewise Therapeutics, Inc.盘中异动 快速上涨5.02%报28.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517193704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517193704?lang=zh_cn&edition=full","pubTime":"2025-03-07 01:38","pubTimestamp":1741282683,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日01时38分，Edgewise Therapeutics, Inc.股票出现异动，股价大幅上涨5.02%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.96%。其相关个股中，Plus Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Aeon Biopharma, Inc.涨幅较大，Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为3907.56%、3160.30%、227.79%，振幅较大的相关个股有Surrozen Inc C/Wts 01/08/2031 、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为125.28%、122.63%、71.44%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307013803abeba4d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307013803abeba4d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","EWTX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514870347","title":"Edgewise Therapeutics, Inc.盘中异动 快速跳水5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514870347","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514870347?lang=zh_cn&edition=full","pubTime":"2025-02-25 03:47","pubTimestamp":1740426440,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日03时47分，Edgewise Therapeutics, Inc.股票出现波动，股价快速下挫5.10%。截至发稿，该股报25.69美元/股，成交量40.8569万股，换手率0.43%，振幅5.62%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.28%。其相关个股中，Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为324.52%、138.11%、40.17%，振幅较大的相关个股有Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为176.22%、162.04%、81.92%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225034720a25256d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225034720a25256d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","EWTX","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513973732","title":"Edgewise Therapeutics, Inc.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513973732","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513973732?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:06","pubTimestamp":1740154017,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日00时06分，Edgewise Therapeutics, Inc.股票出现异动，股价大幅上涨5.02%。截至发稿，该股报28.46美元/股，成交量30.7464万股，换手率0.32%，振幅5.20%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。其相关个股中，Osr Holdings, Inc.、Nkgen Biotech, Inc.、Osr Holdings Inc C/Wts 09/02/2028 涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为189.92%、135.39%、117.09%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为67.41%、57.50%、48.19%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000658988df2a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000658988df2a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","BK4539","LENZ","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512193146","title":"Edgewise Therapeutics, Inc.盘中异动 股价大涨5.00%报26.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512193146","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512193146?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:06","pubTimestamp":1739901960,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日02时06分，Edgewise Therapeutics, Inc.股票出现波动，股价快速拉升5.00%。截至发稿，该股报26.66美元/股，成交量48.6326万股，换手率0.51%，振幅4.84%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.66%。其相关个股中，Aditxt, Inc.、Solid Biosciences Inc.、Allogene Therapeutics, Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为640.36%、196.30%、163.51%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190206009627babe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190206009627babe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EWTX","BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503408936","title":"Edgewise Therapeutics, Inc.盘中异动 大幅上涨5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503408936","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503408936?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:39","pubTimestamp":1736951949,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时39分，Edgewise Therapeutics, Inc.股票出现异动，股价急速上涨5.83%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.67%。其相关个股中，Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Dermata Therapeutics Inc C/Wts 、Exicure, Inc.涨幅较大，Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Oncolytics Biotech Inc.较为活跃，换手率分别为188.25%、79.81%、36.02%，振幅较大的相关个股有Eterna Therapeutics Inc.、180 Life Sciences Corp C/Wts 07/11/2025、Onconetix, Inc.，振幅分别为21.55%、18.45%、16.94%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011522390998673d66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011522390998673d66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","EWTX","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503368235","title":"【纳斯达克生物科技指数收跌1.84%】 成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503368235","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503368235?lang=zh_cn&edition=full","pubTime":"2025-01-15 05:31","pubTimestamp":1736890304,"startTime":"0","endTime":"0","summary":"成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/15053147459494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TQQQ","TVGN","USJW.SI","BK1147","03086","BK4539","NQmain","PSQ","NDX","QLD",".IXIC","USAW.SI","MNQmain","QID","BK4007","BK4139","159632","TSYW.SI","EWTX","159837","LENZ","NVIW.SI","SQQQ","ARTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501253831","title":"Edgewise Therapeutics, Inc.盘中异动 早盘急速下挫5.70%报26.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501253831","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501253831?lang=zh_cn&edition=full","pubTime":"2025-01-06 22:44","pubTimestamp":1736174681,"startTime":"0","endTime":"0","summary":"北京时间2025年01月06日22时44分，Edgewise Therapeutics, Inc.股票出现异动，股价大幅下挫5.70%。截至发稿，该股报26.14美元/股，成交量2.6499万股，换手率0.03%，振幅2.96%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Scisparc Ltd.、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 涨幅较大，Scisparc Ltd.、Cns Pharmaceuticals, Inc.、Cytomed Therapeutics Limited较为活跃，换手率分别为496.58%、243.25%、83.74%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Scisparc Ltd.、Cytomed Therapeutics Limited，振幅分别为39.34%、34.08%、33.91%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106224441a2179963&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106224441a2179963&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","EWTX","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486827077","title":"Edgewise Therapeutics, Inc.盘中异动 早盘股价大涨5.80%报33.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486827077","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486827077?lang=zh_cn&edition=full","pubTime":"2024-11-27 22:31","pubTimestamp":1732717860,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日22时31分，Edgewise Therapeutics, Inc.股票出现异动，股价大幅拉升5.80%。截至发稿，该股报33.94美元/股，成交量1447股，换手率0.00%，振幅0.00%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Celularity Inc C/Wts 16/07/2026 、Cyclerion Therapeutics, Inc.、Tuhura Biosciences, Inc.涨幅较大，Cyclerion Therapeutics, Inc.、Outlook Therapeutics, Inc.、Molecular Templates, Inc.较为活跃，换手率分别为784.53%、23.12%、6.72%，振幅较大的相关个股有Cyclerion Therapeutics, Inc.、Elevai Labs, Inc.、Oragenics Inc.，振幅分别为13.97%、8.20%、6.38%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127223100971a8dab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127223100971a8dab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","EWTX","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483218306","title":"Edgewise Therapeutics, Inc.2024财年第三财季实现净利润-34.13百万美元，同比减少32.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483218306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483218306?lang=zh_cn&edition=full","pubTime":"2024-11-16 00:00","pubTimestamp":1731686435,"startTime":"0","endTime":"0","summary":"11月16日，Edgewise Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-34.13百万美元，同比减少32.75%；其中营业收入为0.00美元，每股基本收益为-0.36美元。从资产负债表来看，Edgewise Therapeutics, Inc.总负债22.41百万美元，其中短期债务992000.00美元，资产负债比为0.23，流动比率为0.27。机构评级：截至2024年11月16日，当前有6家机构对Edgewise Therapeutics, Inc.目标价做出预测，其中目标均价为43.17美元，其中最低目标价为33.00美元，最高目标价为51.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000316a23b89cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000316a23b89cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EWTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483513358","title":"Edgewise Therapeutics, Inc.盘中异动 下午盘大幅下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483513358","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483513358?lang=zh_cn&edition=full","pubTime":"2024-11-14 03:38","pubTimestamp":1731526720,"startTime":"0","endTime":"0","summary":"北京时间2024年11月14日03时38分，Edgewise Therapeutics, Inc.股票出现异动，股价快速下跌5.06%。截至发稿，该股报33.42美元/股，成交量32.2608万股，换手率0.34%，振幅6.39%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.42%。其相关个股中，Nkgen Biotech Inc C/Wts 31/05/2028、Pulmatrix, Inc.、Calidi Biotherapeutics, Inc.涨幅较大，Elevai Labs, Inc.、Cyclacel Pharmaceuticals, Inc.、Calidi Biotherapeutics, Inc.较为活跃，换手率分别为619.13%、553.18%、161.95%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Pulmatrix, Inc.、Celularity Inc C/Wts 16/07/2026 ，振幅分别为139.00%、86.83%、73.71%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114033841a234ea0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114033841a234ea0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EWTX","BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481587130","title":"Edgewise Therapeutics, Inc.盘中异动 下午盘大幅下挫5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481587130","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481587130?lang=zh_cn&edition=full","pubTime":"2024-11-08 02:47","pubTimestamp":1731005250,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日02时47分，Edgewise Therapeutics, Inc.股票出现异动，股价快速下挫5.02%。截至发稿，该股报34.78美元/股，成交量39.4834万股，换手率0.42%，振幅5.68%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.93%。其相关个股中，Celularity Inc.、Celularity Inc C/Wts 16/07/2026 、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Ensysce Biosciences, Inc.、Elevai Labs, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为935.26%、495.75%、119.36%，振幅较大的相关个股有Celularity Inc.、Celularity Inc C/Wts 16/07/2026 、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为258.62%、193.53%、72.18%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110802473098e41453&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110802473098e41453&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","EWTX","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.edgewisetx.com","stockEarnings":[{"period":"1week","weight":-0.0822},{"period":"1month","weight":-0.0787},{"period":"3month","weight":0.0545},{"period":"6month","weight":0.4199},{"period":"1year","weight":1.1461},{"period":"ytd","weight":0.2783}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Edgewise Therapeutics, Inc.于2017年5月在特拉华州注册成立。该公司是一家以科学为驱动的生物技术公司，专注于开发针对严重肌肉疾病的疗法，最初目标是罕见神经肌肉和心脏疾病。其主要候选药物sevasemten是一种口服小分子抑制剂，正处于治疗杜氏肌营养不良和贝克尔肌营养不良的后期临床开发阶段。","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.169596},{"month":2,"riseRate":0.2,"avgChangeRate":-0.053086},{"month":3,"riseRate":0.4,"avgChangeRate":-0.097717},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.044897},{"month":5,"riseRate":0.5,"avgChangeRate":-0.034116},{"month":6,"riseRate":0.4,"avgChangeRate":-0.050464},{"month":7,"riseRate":0.4,"avgChangeRate":0.001937},{"month":8,"riseRate":0.6,"avgChangeRate":-0.017665},{"month":9,"riseRate":0.6,"avgChangeRate":0.09895},{"month":10,"riseRate":0.6,"avgChangeRate":0.092429},{"month":11,"riseRate":0.4,"avgChangeRate":0.07088},{"month":12,"riseRate":0.2,"avgChangeRate":0.087485}],"exchange":"NASDAQ","name":"Edgewise Therapeutics, Inc.","nameEN":"Edgewise Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Edgewise Therapeutics, Inc.(EWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Edgewise Therapeutics, Inc.(EWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Edgewise Therapeutics, Inc.,EWTX,Edgewise Therapeutics, Inc.股票,Edgewise Therapeutics, Inc.股票老虎,Edgewise Therapeutics, Inc.股票老虎国际,Edgewise Therapeutics, Inc.行情,Edgewise Therapeutics, Inc.股票行情,Edgewise Therapeutics, Inc.股价,Edgewise Therapeutics, Inc.股市,Edgewise Therapeutics, Inc.股票价格,Edgewise Therapeutics, Inc.股票交易,Edgewise Therapeutics, Inc.股票购买,Edgewise Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Edgewise Therapeutics, Inc.(EWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Edgewise Therapeutics, Inc.(EWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}